3 Stocks Likely to Benefit from the GLP-1 Boom: TDOC, OLLI, DXCM

The GLP-1 revolution continues quietly as investor interest shifts to more timely topics. One of the best ways to get into the fast-growing drug space is through manufacturers like Novo Nordisk NYSE: NVO or Eli Lilly NYSE: LLYleading companies responsible for developing and manufacturing products such as Ozempic and Zepbound.

There are, of course, indirect ways investors can benefit from the GLP-1 rush. The prospect of the market tripling in size in the coming years has enticed a number of other drug developers to work on their offerings, and a number of emerging firms may be worth watching—or investors can look to dedicated exchange-traded funds (ETFs) like the Roundhill GLP-1 & Weight Loss ETF. NASDAQ: OZEM to get a broader view.

But the impact of GLP-1 agonists extends beyond the pharma space, and downstream companies can benefit from the trend despite their lack of direct involvement.

GLP-1 Telehealth Business Poised for Growth

Teladoc Health NYSE: TDOC operates a telehealth platform that provides patients with virtual care services related to obesity management and metabolic health, among other services.

These areas of Teladoc’s business, along with the GLP-1 prescription implementation, are growing very quickly. The company is simply making it as easy as possible for qualified patients to gain access to GLP-1 therapy, which could be a game-changer for those who don’t have easy access to in-person specialists.

This had a real impact on Teladoc’s results. In Q1 2026, for example, the company beat revenue expectations by nearly $3 million at $614 million, and adjusted EBITDA of $58 million also came in ahead of guidance. Visit-based care is enhanced by 24/7 AI-enabled offerings that are likely to be a driver of sales and revenues throughout the year at least.

At the same time, Teladoc is working to repair its balance sheet by beginning a multi-step debt reduction process and plans to reduce its stock-based compensation to $55 million or less next year. The company also built its financial strength with cash reserves that reached $751 million at the end of the first quarter.

This is a welcome change for investors after several consecutive quarters of sluggish health, as indicated by TradeSmith’s health index in the red.

GLP-1 Customers Buying New Clothes Could Fuel This Retailer’s Growth

Discount retailer Ollie’s Bargain Outlet NASDAQ: OLLI it may seem like an unexpected beneficiary of GLP-1 drugs, but this and other similar clothing stores can play a very important role in patients who lose weight and need to buy new clothes.

Ollie’s Bargain Outlet Today

OLLI

Ollie’s Bargain Outlet

$76.91 0.00 (0.00%)

As of 06/18/2026 04:00 PM Eastern

52 week interval

$73.32

▼

$141.74

The P/E ratio

18.99

Target Value

$125.13

Ollie’s is among the most aggressive discount clothing retailers in terms of pricing and may be in a good position to gain business from GLP-1 patients who want to replace a large volume of clothing quickly.

In Q1 2026, Ollie reported strong results overall, including sales growth of 14% year-on-year (YOY) and retail sales improvement of 1.7% over the same period.

Adjusted earnings per share (EPS) rose 21% YOY as well, despite headwinds including lower inflation and higher fuel prices.

Ollie’s is also growing rapidly, with 27 new stores opening in the first half of the year and 75 planned new openings in total this year.

OLLI stock is an Average Buy across Wall Street, based on 14 buy ratings and three holds. Shares are down about 30% year-to-date (YTD) but are still about 60% above potential based on analyst estimates.

Glucose Monitoring Devices May Grow in Popularity

Although not a pharmaceutical company, DexCom is for the healthcare industry NASDAQ: DXCM is a medical device firm that can benefit from the GLP-1 trend because of its continuous glucose monitoring (CGM) devices. CGM is essential for GLP-1 patients with type 2 diabetes, making these products a useful companion to GLP-1 therapy in some cases.

DexCom today

$72.47 0.00 (0.00%)

As of 06/18/2026 04:00 PM Eastern

52 week interval

$54.11

▼

$89.98

The P/E ratio

30.97

Target Value

$84.83

Care providers may increasingly look to CGMs and GLP-1s as an integrated solution for patients with diabetes. CGMs have long been associated with insulin treatment, but the rapid increase in GLP-1s outside the number of diabetic patients has the potential to open the monitoring needs of those interested in tracking glucose trends even if they do not use insulin. DexCom responded by introducing a wide range of over-the-counter products.

Overall, more people becoming more aware of metabolic health and interested in monitoring their sugar levels could mean more business for DexCom. This may contribute to DexCom’s strong reputation among analysts: the stock has 22 buy ratings compared to three holds and one sell, and 17% of predicted strength.

Before you consider Teladoc Health, you’ll want to hear this.

MarketBeat tracks Wall Street’s top and most effective research analysts and the stocks they recommend to their clients every day. MarketBeat identified five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Teladoc Health was not on the list.

Although Teladoc Health currently has a hold rating among analysts, senior analysts believe these five stocks are a better buy.

View Five Stocks Here

Click the link to see MarketBeat’s list of seven stocks and why their long-term outlooks are so promising.

Get This Free Report

Do you like this article? Share with your colleagues.

The link is copied to the clipboard.